Thus, disease-modifying, tau targeting therapies are expected to be most beneficial in early symptomatic patients when a high degree of function can still be preserved – primarily AD Stages 3 (MCI) and 4 (AD mild). The gene discussed is MAPT; the disease is Alzheimer disease.